KRAS and colorectal carcinoma: Having shown that BRG1 expression for CRC treated with CBZ is dependent on the presence of a KRAS mutation, we performed qPCR analysis to determine mRNA expression of SMARCA4 after 6 and 24 h of CBZ treatment.